
Hematology-OncologyAcute Lymphoblastic Leukemiainotuzumab ozogamicin
Synergistic Therapy with Venetoclax and Inotuzumab Ozogamicin Shows Promising Outcomes in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
By MedXY|Sep 30, 2026
A phase 1 trial demonstrates that venetoclax combined with inotuzumab ozogamicin is safe and highly effective in producing durable MRD-negative remissions in relapsed/refractory B-cell ALL and lymphoblastic lymphoma.
